TRIM33 and dermatomyositis: Defining additional autoantibody specificities that are enriched in anti–TIF1-γ–positive DM patients in whom cancer does not emerge could therefore provide insights into the mechanisms underlying the cancer-DM association and inform cancer screening strategies in the clinic.